prevention of re-occurrence of disease

Prevention of the recurrence of AD – JEL3108

Carocell Bio is more than just a name; it’s an evolution in skin care.

Spearheading a movement, we are harnessing peptide-based anti-inflammatory technology to more safely treat skin-related conditions. Discovered by AstraZeneca, our peptides are a weapon against skin-related inflammation and ageing.

As a bridge between innovating science and unmet patient needs, we are set to alter the course of treatments available, delivering tangible benefits demonstrated in both cellular and human biopsy studies.

Our lead peptide, JEL3108, will be formulated for topical application, making it a powerful ally against the skin disease atopic dermatitis (eczema) and with continued treatment will prevent the disease from coming back.

Eczema (atopic dermatitis) is well known as a recurrent disease.  Current treatments are stopped after a relatively short period because of safely issues.  Everyone knows the problems with topical steroids – they work, but…. 

‘Parents hate putting steroids on baby’s faces’

(Emma Roberts, parent, personal experience, June 2023)

One of the additional benefits of Carocell Bio’s novel peptide treatments for eczema is that it is a peptide (small protein) that will be safely broken down into naturally occurring amino acids.

At Carocell Bio, we have shown that JEL3108 significantly reduces inflammation in cellular studies (Figures 1 and 2), and it also prevents the activation of inflammation by blocking the re-activation of our target enzyme (Figure 5).  The allosterically-binding MAP kinase  peptide inhibitor JEL3108, additionally prevents the phosphorylation of the kinase (Figure 3).

inhibits activation

These data together indicate that our lead peptide, JEL3108, will not only treat eczema – as demonstrated in cell and human tissue biopsy studies – but, if continued, it will prevent the disease coming back.

OUR RESEARCH

Find out more about our therapeutic peptides and how they can reduce inflammation in a host of serious inflammatory diseases.

PRESENTATION SLIDES

For further information and access to detailed documentation, please get in touch.